Fig. 2: PD-L1 high-expression reduced HIS with tumor progression. | Cell Death & Disease

Fig. 2: PD-L1 high-expression reduced HIS with tumor progression.

From: High baseline levels of PD-L1 reduce the heterogeneity of immune checkpoint signature and sensitize anti-PD1 therapy in lung and colorectal cancers

Fig. 2: PD-L1 high-expression reduced HIS with tumor progression.

A Schematic diagram of tumor immune evasion mediated by HIS: immune checkpoints express at low levels during tumor initiation (HIS-low), and tumor progression requires stronger immune evasion capabilities via either randomly upregulating multiple immune checkpoints (HIS-high) or overexpressing a few immune checkpoints (HIS-low). B Volcano plot displaying differentially upregulated (pink dots) and downregulated (blue dots) genes, comparing small or large pCDH and PD-L1 tumors, with a threshold of |log2-fold change (fc)| >1 and FDR < 0.05. C Top 5 GO terms of downregulated gene enrichment in large MCA38 tumors. D GSEA indicating negative enrichment of genes related to negative regulation of immune responses in large MCA38-PD-L1 tumors compared to control MCA38-pCDH tumors. P values were automatically determined by GSEA v.3.0. ES, enrichment score; NES, normalized enrichment score; FDR, false discovery rate. E, F The sample distribution plot (left) illustrated the profiles of immune checkpoint gene expression for pCDH (red) and PD-L1 (blue) in MCA38 and LAP tumors based on RNAseq data. The corresponding heatmap (right) showed group-level representations, with three biological replicates (n = 3) for MCA38 tumors and five biological replicates (n = 5) for LAP tumors.

Back to article page